Of the 467 patients, 136 (29.31%) were in the low-risk group (T1 stage with one positive lymph node), 189 (40.73%) were in the intermediate-risk group (T1 stage with two to three positive lymph nodes, T2 stage with one positive lymph node, or T1 stage with ER-positive and HER2 positive tumor), and 139 (29.96%) were in the high-risk group (T2 stage with two to three positive lymph nodes or a tumor-proven immunohistochemically to be TNBC). This evidence concerns the gene ERBB2 and neoplasm.